GREY:CBICF - Post by User
Post by
bogdanszon Jan 15, 2019 6:53am
208 Views
Post# 29231825
Price Target for iAnthus US $ 16 . Merger with MPX explosive
Price Target for iAnthus US $ 16 . Merger with MPX explosiveStanley has not altered his estimates for IAN and has reiterated his Buy rating and C$16.00 target price, which represents a 12-month return of 168 per cent at the time of publication. Related Posts iAnthus Capital has 120 per cent upside, Beacon Securities says US cannabis company iAnthus Capital Holdings (iAnthus Capital Stock Quote, Chart CSE:IAN) recently announced an Ianthus Capital is a double, Beacon Securities says In a coverage resumption on Thursday, Beacon Securities analyst Russell Stanley rates US cannabis company The Supreme Cannabis Company has 93 per cent upside, GMP says With a healthy balance sheet and improving results, GMP Securities analyst Robert Fagan thinks The FILED UNDER:ALL POSTS,CANNABISTAGGED WITH:IAN AboutJayson MacLean Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas. Primary Sidebar TRENDING The 10 Best Performing TSX Venture Tech Stocks of 2018 Aphria gets Buy rating back at GMP Securities The 10 Best Performing TSX Tech Stocks of 2018 BlackBerry is protected from the US-China trade war, CEO says Nubeva Technologies has a huge upside, Echelon Wealth says Search this website NEWSWIRE Trend Micro Increases Commitment To Secure The Connected World at Pwn2Own 2019 BP Logix and DesTech Announce BPM Technology Partnership KIK Custom Products Selects Astute Software Suite for More Efficient & Insightful Consumer Care Smiths Detection Wins New Contract with DHS Countering Weapons of Mass Destruction Office Datacolor Partners with Color Solutions International to Improve Textile Color Identification with ColorReaderPRO All news EDITORS PICKS Echelon Wealth Partners reveals its Top Stock Picks for 2019 Theres still tons of upside in Acerus Pharmaceuticals, Mackie Research says Medical cannabis companies will be the clear winners in the pot sector, Paradigm Capital says Get top stories in your inbox Secondary Sidebar